search
Back to results

Expanded Access for Marizomib

Primary Purpose

Solid Tumor

Status
No longer available
Phase
Locations
United States
Study Type
Expanded Access
Intervention
Marizomib
Sponsored by
Celgene
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Solid Tumor focused on measuring Expanded Access, Compassionate Use

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All Sexes

Inclusion Criteria:

-

Exclusion Criteria:

-

Sites / Locations

  • Bristol Myers Squibb

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 19, 2020
Last Updated
November 19, 2020
Sponsor
Celgene
search

1. Study Identification

Unique Protocol Identification Number
NCT04644107
Brief Title
Expanded Access for Marizomib
Official Title
Expanded Access for Marizomib
Study Type
Expanded Access

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Celgene

4. Oversight

5. Study Description

Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to Marizomib.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor
Keywords
Expanded Access, Compassionate Use

7. Study Design

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Marizomib
Other Intervention Name(s)
CC-92763
Intervention Description
Marizomib will be administered via IV

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria: - Exclusion Criteria: -
Facility Information:
Facility Name
Bristol Myers Squibb
City
Summit
State/Province
New Jersey
ZIP/Postal Code
07901
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Expanded Access for Marizomib

We'll reach out to this number within 24 hrs